Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US

Laxxon Medical, a pharma-technology company, and Adare Pharma Solutions, a global CDMO, announced a strategic partnership. This collaboration aims to enable the cGMP production of Laxxon's 3D screen-printed drug delivery systems at Adare’s certified facilities.

This partnership combines Adare's manufacturing expertise with Laxxon's SPID® Technology, targeting the EU and US markets. Exentis Group, based near Zurich, provides the underlying technology, which Laxxon licensed exclusively for pharmaceutical applications in 2017.

The technology allows for the efficient development and production of complex oral dosage forms. The first production system is set up at Adare's Pessano site in Italy, with another planned for Vandalia, Ohio.

Both CEOs highlighted the importance of this partnership for advancing innovative drug delivery solutions. The new facilities will enhance dose flexibility, R&D capabilities, and manufacturing scale, including granules, capsules, and tablets.